首页> Current pharmaceutical design> A Novel Danshensu-Tetramethylpyrazine Conjugate DT-018 Provides Cardioprotection by Preserving Mitochondrial Function Through the MEF2D/PGC-1 alpha Pathway

A Novel Danshensu-Tetramethylpyrazine Conjugate DT-018 Provides Cardioprotection by Preserving Mitochondrial Function Through the MEF2D/PGC-1 alpha Pathway

导出原文传递

翻译打印收藏纠错

第一作者： Zhang, Xiaojing

作者： Zhang, Xiaojing ^[1] ; Luo, Jingxiong ; Huang, Yali ; Deng, Huixing ; Hu, Huihui ; Yu, Pei ; Sun, Yewei ; Shan, Luchen ; Wang, Yuqiang

作者单位： Jinan Univ, Coll Pharm, Inst New Drug Res, Guangzhou 510632, Guangdong, Peoples R China ^[1]

关键词 Danshensu derivative cardioprotection mitochondrial function preservation ischemia/reperfusion MEF2D/PGC-1 alpha pathway reactive oxygen species (ROS)

发布时间 2018-07-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Current pharmaceutical design

2017年23卷39期

6062-6070页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

Current pharmaceutical design

2017年23卷39期

6062-6070页

检索历史清除

A Novel Danshensu-Tetramethylpyrazine Conjugate DT-018 Provides Cardioprotection by Preserving Mitochondrial Function Through the MEF2D/PGC-1 alpha Pathway

Current pharmaceutical design

相似文献

同项目论文

Current pharmaceutical design

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Novel Danshensu-Tetramethylpyrazine Conjugate DT-018 Provides Cardioprotection by Preserving Mitochondrial Function Through the MEF2D/PGC-1 alpha Pathway

Current pharmaceutical design

相似文献

同项目论文

Current pharmaceutical design

相关期刊

检索历史清除